Enfermedad tromboembólica venosa

:: Cáncer y ETV ::

Enoxaparin versus dalteparin or tinzaparin in patients with cancer and venous thromboembolism: The RIETECAT study

Trujillo-Santos J, Farge-Bancel D, Pedrajas JM, Gómez-Cuervo C, Ballaz A, Braester A, Mahé I, Villalobos A, Porras JA, Monreal M; RIETE Investigators.

Referencia: Res Pract Thromb Haemost. 2022 Jun 3;6(4):e12736.

Outcome of cancer-associated venous thromboembolism is more favorable among patients with hematologic malignancies than in those with solid tumors

Lecumberri R, Ruiz-Artacho P, Tzoran I, Brenner B, Farge Bancel D, Ay C, Rosa V, Iria F, Hernández-Blasco L, Trujillo Santos J, Monreal M.

Referencia: Thromb Haemost. 2022 Feb 21. Epub ahead of print.

Clinical characteristics and 3-month outcomes in cancer patients with incidental versus clinically suspected and confirmed pulmonary embolism

Peris M, López-Nuñez JJ, Maestre A, Jiménez D, Muriel A, Bikdeli B, Weinberg I, Ay C, Mazzolai L, Lorenzo A, Monreal M; RIETE Investigators.

Referencia: Eur Respir J. 2021 Jul 1;58(1):2002723.